Immunogenicity and efficacy study of a commercial Borrelia burgdorferi bacterin

Hsien-Jue Chu From the Fort Dodge Laboratories, 800 Fifth St NW, Fort Dodge, IA 50501.

Search for other papers by Hsien-Jue Chu in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Lloyd G. Chavez Jr. From the Fort Dodge Laboratories, 800 Fifth St NW, Fort Dodge, IA 50501.

Search for other papers by Lloyd G. Chavez Jr. in
Current site
Google Scholar
PubMed
Close
 PhD
,
Barbara M. Blumer From the Fort Dodge Laboratories, 800 Fifth St NW, Fort Dodge, IA 50501.

Search for other papers by Barbara M. Blumer in
Current site
Google Scholar
PubMed
Close
 BS
,
Randal W. Sebring From the Fort Dodge Laboratories, 800 Fifth St NW, Fort Dodge, IA 50501.

Search for other papers by Randal W. Sebring in
Current site
Google Scholar
PubMed
Close
 DVM
,
Terri L. Wasmoen From the Fort Dodge Laboratories, 800 Fifth St NW, Fort Dodge, IA 50501.

Search for other papers by Terri L. Wasmoen in
Current site
Google Scholar
PubMed
Close
 PhD
, and
William M. Acree From the Fort Dodge Laboratories, 800 Fifth St NW, Fort Dodge, IA 50501.

Search for other papers by William M. Acree in
Current site
Google Scholar
PubMed
Close
 BS

Summary

The immunogenicity and efficacy of a commercial Borrelia burgdorferi bacterin was evaluated for stimulation of the host immune response and protection against clinical disease associated with experimentally induced borreliosis in dogs. A total of 30 vaccinated and 24 control dogs were used in 3 separate studies. The vaccine was given im as two 1-ml doses separated by a 3-week interval. Two weeks or 5 months following the last vaccination, the dogs were challenge inoculated with 7 daily doses of a virulent preparation of a B burgdorferi field isolate through intraperitoneal, subcutaneous, and intradermal routes with or without glucocorticoid administration at the same time. The development of B burgdorferi spirochetemia and clinical disease in the dogs after challenge exposure was studied. Serum samples were obtained from the dogs at various times during the study for serum neutralizing antibody determination and protein immunoblot antibody assay against various geographic isolates of B burgdorferi. Challenge exposure induced limb/joint disorder, fever, anorexia, signs of depression, and B burgdorferi spirochetemia in the nonvaccinated control dogs. The vaccine was found to elicit cross-reactive serum neutralizing and protein immunoblot antibody responses in dogs to various isolates of B burgdorferi and to protect the vaccinated dogs against experimentally induced borreliosis.

Summary

The immunogenicity and efficacy of a commercial Borrelia burgdorferi bacterin was evaluated for stimulation of the host immune response and protection against clinical disease associated with experimentally induced borreliosis in dogs. A total of 30 vaccinated and 24 control dogs were used in 3 separate studies. The vaccine was given im as two 1-ml doses separated by a 3-week interval. Two weeks or 5 months following the last vaccination, the dogs were challenge inoculated with 7 daily doses of a virulent preparation of a B burgdorferi field isolate through intraperitoneal, subcutaneous, and intradermal routes with or without glucocorticoid administration at the same time. The development of B burgdorferi spirochetemia and clinical disease in the dogs after challenge exposure was studied. Serum samples were obtained from the dogs at various times during the study for serum neutralizing antibody determination and protein immunoblot antibody assay against various geographic isolates of B burgdorferi. Challenge exposure induced limb/joint disorder, fever, anorexia, signs of depression, and B burgdorferi spirochetemia in the nonvaccinated control dogs. The vaccine was found to elicit cross-reactive serum neutralizing and protein immunoblot antibody responses in dogs to various isolates of B burgdorferi and to protect the vaccinated dogs against experimentally induced borreliosis.

Advertisement